522 related articles for article (PubMed ID: 28303311)
1. [Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
Neubauer A
Internist (Berl); 2017 Apr; 58(4):409-423. PubMed ID: 28303311
[TBL] [Abstract][Full Text] [Related]
2. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
6. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
8. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
9. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
10. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
12. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
13. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
[TBL] [Abstract][Full Text] [Related]
14. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunology and melanoma immunotherapy.
Linck RDM; Costa RLP; Garicochea B
An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
[TBL] [Abstract][Full Text] [Related]
16. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
[TBL] [Abstract][Full Text] [Related]
17. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
19. New Immunotherapy and Lung Cancer.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
[TBL] [Abstract][Full Text] [Related]
20. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Bertrand F; Montfort A; Marcheteau E; Imbert C; Gilhodes J; Filleron T; Rochaix P; Andrieu-Abadie N; Levade T; Meyer N; Colacios C; Ségui B
Nat Commun; 2017 Dec; 8(1):2256. PubMed ID: 29273790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
